nodes	percent_of_prediction	percent_of_DWPC	metapath
Bicalutamide—Androgen Receptor Antagonists—Flutamide—prostate cancer	0.221	0.5	CiPCiCtD
Bicalutamide—Androgen Receptor Antagonists—Nilutamide—prostate cancer	0.221	0.5	CiPCiCtD
Bicalutamide—Enzalutamide—Nilutamide—prostate cancer	0.205	1	CrCrCtD
Bicalutamide—AR—prostate cancer	0.0588	0.497	CbGaD
Bicalutamide—AR—Nilutamide—prostate cancer	0.0388	0.259	CbGbCtD
Bicalutamide—CYP2C19—prostate cancer	0.0363	0.307	CbGaD
Bicalutamide—AR—Flutamide—prostate cancer	0.0322	0.215	CbGbCtD
Bicalutamide—CYP3A4—prostate cancer	0.0231	0.195	CbGaD
Bicalutamide—AR—Estradiol—prostate cancer	0.0134	0.0892	CbGbCtD
Bicalutamide—CYP2C19—Nilutamide—prostate cancer	0.00713	0.0476	CbGbCtD
Bicalutamide—CYP3A4—Estradiol valerate/Dienogest—prostate cancer	0.00656	0.0438	CbGbCtD
Bicalutamide—CYP2C9—Nilutamide—prostate cancer	0.00592	0.0396	CbGbCtD
Bicalutamide—CYP2C19—Flutamide—prostate cancer	0.0059	0.0394	CbGbCtD
Bicalutamide—CYP2D6—Abiraterone—prostate cancer	0.00449	0.03	CbGbCtD
Bicalutamide—CYP2C9—Estrone—prostate cancer	0.00355	0.0237	CbGbCtD
Bicalutamide—CYP3A4—Estramustine—prostate cancer	0.0032	0.0214	CbGbCtD
Bicalutamide—CYP3A4—Flutamide—prostate cancer	0.00285	0.0191	CbGbCtD
Bicalutamide—CYP3A4—Abiraterone—prostate cancer	0.00285	0.0191	CbGbCtD
Bicalutamide—CYP2C9—Capecitabine—prostate cancer	0.00269	0.018	CbGbCtD
Bicalutamide—CYP2C19—Estradiol—prostate cancer	0.00245	0.0164	CbGbCtD
Bicalutamide—CYP3A4—Cabazitaxel—prostate cancer	0.00211	0.0141	CbGbCtD
Bicalutamide—CYP2C19—Prednisone—prostate cancer	0.00211	0.0141	CbGbCtD
Bicalutamide—CYP3A4—Estrone—prostate cancer	0.00206	0.0138	CbGbCtD
Bicalutamide—CYP2C9—Estradiol—prostate cancer	0.00204	0.0136	CbGbCtD
Bicalutamide—CYP3A4—Ethinyl Estradiol—prostate cancer	0.00184	0.0123	CbGbCtD
Bicalutamide—AR—penis—prostate cancer	0.00148	0.195	CbGeAlD
Bicalutamide—AR—semen—prostate cancer	0.00141	0.186	CbGeAlD
Bicalutamide—CYP3A4—Conjugated Estrogens—prostate cancer	0.00135	0.00902	CbGbCtD
Bicalutamide—CYP3A4—Mitoxantrone—prostate cancer	0.00123	0.0082	CbGbCtD
Bicalutamide—CYP3A4—Estradiol—prostate cancer	0.00119	0.00792	CbGbCtD
Bicalutamide—CYP3A4—Prednisone—prostate cancer	0.00102	0.00681	CbGbCtD
Bicalutamide—CYP2C19—urine—prostate cancer	0.000911	0.12	CbGeAlD
Bicalutamide—CYP2D6—Doxorubicin—prostate cancer	0.00083	0.00555	CbGbCtD
Bicalutamide—CYP3A4—Etoposide—prostate cancer	0.000774	0.00517	CbGbCtD
Bicalutamide—CYP3A4—Docetaxel—prostate cancer	0.000708	0.00473	CbGbCtD
Bicalutamide—CYP2C9—urine—prostate cancer	0.000706	0.0933	CbGeAlD
Bicalutamide—CYP3A4—urine—prostate cancer	0.000538	0.0711	CbGeAlD
Bicalutamide—CYP2D6—urine—prostate cancer	0.00053	0.07	CbGeAlD
Bicalutamide—CYP3A4—Doxorubicin—prostate cancer	0.000528	0.00353	CbGbCtD
Bicalutamide—AR—prostate gland—prostate cancer	0.000353	0.0466	CbGeAlD
Bicalutamide—Enzalutamide—AR—prostate cancer	0.000327	0.343	CrCbGaD
Bicalutamide—AR—seminal vesicle—prostate cancer	0.000298	0.0394	CbGeAlD
Bicalutamide—Enzalutamide—CYP3A5—prostate cancer	0.000297	0.311	CrCbGaD
Bicalutamide—AR—epithelium—prostate cancer	0.000259	0.0342	CbGeAlD
Bicalutamide—AR—renal system—prostate cancer	0.00024	0.0318	CbGeAlD
Bicalutamide—AR—urethra—prostate cancer	0.000236	0.0312	CbGeAlD
Bicalutamide—Enzalutamide—CYP2C19—prostate cancer	0.000202	0.212	CrCbGaD
Bicalutamide—AR—testis—prostate cancer	0.000155	0.0205	CbGeAlD
Bicalutamide—CYP3A4—renal system—prostate cancer	0.000132	0.0174	CbGeAlD
Bicalutamide—CYP2D6—renal system—prostate cancer	0.00013	0.0171	CbGeAlD
Bicalutamide—Enzalutamide—CYP3A4—prostate cancer	0.000129	0.135	CrCbGaD
Bicalutamide—AR—lymph node—prostate cancer	0.000113	0.0149	CbGeAlD
Bicalutamide—CYP2D6—testis—prostate cancer	8.38e-05	0.0111	CbGeAlD
Bicalutamide—Shock—Capecitabine—prostate cancer	9.42e-06	0.000179	CcSEcCtD
Bicalutamide—Rhinitis—Epirubicin—prostate cancer	9.41e-06	0.000179	CcSEcCtD
Bicalutamide—Abdominal pain—Etoposide—prostate cancer	9.41e-06	0.000179	CcSEcCtD
Bicalutamide—Body temperature increased—Etoposide—prostate cancer	9.41e-06	0.000179	CcSEcCtD
Bicalutamide—Urinary tract infection—Doxorubicin—prostate cancer	9.41e-06	0.000179	CcSEcCtD
Bicalutamide—Conjunctivitis—Doxorubicin—prostate cancer	9.41e-06	0.000179	CcSEcCtD
Bicalutamide—Nervous system disorder—Capecitabine—prostate cancer	9.39e-06	0.000178	CcSEcCtD
Bicalutamide—Haemorrhage—Epirubicin—prostate cancer	9.39e-06	0.000178	CcSEcCtD
Bicalutamide—Thrombocytopenia—Capecitabine—prostate cancer	9.38e-06	0.000178	CcSEcCtD
Bicalutamide—Syncope—Prednisone—prostate cancer	9.37e-06	0.000178	CcSEcCtD
Bicalutamide—Pharyngitis—Epirubicin—prostate cancer	9.32e-06	0.000177	CcSEcCtD
Bicalutamide—Skin disorder—Capecitabine—prostate cancer	9.3e-06	0.000177	CcSEcCtD
Bicalutamide—Sweating—Doxorubicin—prostate cancer	9.28e-06	0.000176	CcSEcCtD
Bicalutamide—Urinary tract disorder—Epirubicin—prostate cancer	9.27e-06	0.000176	CcSEcCtD
Bicalutamide—Hyperhidrosis—Capecitabine—prostate cancer	9.26e-06	0.000176	CcSEcCtD
Bicalutamide—Oedema peripheral—Epirubicin—prostate cancer	9.25e-06	0.000176	CcSEcCtD
Bicalutamide—Haematuria—Doxorubicin—prostate cancer	9.23e-06	0.000175	CcSEcCtD
Bicalutamide—Urethral disorder—Epirubicin—prostate cancer	9.21e-06	0.000175	CcSEcCtD
Bicalutamide—Loss of consciousness—Prednisone—prostate cancer	9.19e-06	0.000174	CcSEcCtD
Bicalutamide—Hepatobiliary disease—Doxorubicin—prostate cancer	9.15e-06	0.000174	CcSEcCtD
Bicalutamide—Epistaxis—Doxorubicin—prostate cancer	9.13e-06	0.000173	CcSEcCtD
Bicalutamide—Anorexia—Capecitabine—prostate cancer	9.13e-06	0.000173	CcSEcCtD
Bicalutamide—Nausea—Estradiol—prostate cancer	9.12e-06	0.000173	CcSEcCtD
Bicalutamide—Vomiting—Mitoxantrone—prostate cancer	9.1e-06	0.000173	CcSEcCtD
Bicalutamide—Sinusitis—Doxorubicin—prostate cancer	9.08e-06	0.000172	CcSEcCtD
Bicalutamide—Visual impairment—Epirubicin—prostate cancer	9.05e-06	0.000172	CcSEcCtD
Bicalutamide—Hypertension—Prednisone—prostate cancer	9.02e-06	0.000171	CcSEcCtD
Bicalutamide—Rash—Mitoxantrone—prostate cancer	9.02e-06	0.000171	CcSEcCtD
Bicalutamide—Dermatitis—Mitoxantrone—prostate cancer	9.01e-06	0.000171	CcSEcCtD
Bicalutamide—Musculoskeletal discomfort—Docetaxel—prostate cancer	9.01e-06	0.000171	CcSEcCtD
Bicalutamide—Headache—Mitoxantrone—prostate cancer	8.96e-06	0.00017	CcSEcCtD
Bicalutamide—Insomnia—Docetaxel—prostate cancer	8.95e-06	0.00017	CcSEcCtD
Bicalutamide—Myalgia—Prednisone—prostate cancer	8.9e-06	0.000169	CcSEcCtD
Bicalutamide—Paraesthesia—Docetaxel—prostate cancer	8.88e-06	0.000169	CcSEcCtD
Bicalutamide—Anxiety—Prednisone—prostate cancer	8.87e-06	0.000168	CcSEcCtD
Bicalutamide—Bradycardia—Doxorubicin—prostate cancer	8.85e-06	0.000168	CcSEcCtD
Bicalutamide—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	8.84e-06	0.000168	CcSEcCtD
Bicalutamide—Dyspnoea—Docetaxel—prostate cancer	8.82e-06	0.000167	CcSEcCtD
Bicalutamide—Somnolence—Docetaxel—prostate cancer	8.79e-06	0.000167	CcSEcCtD
Bicalutamide—Hypersensitivity—Etoposide—prostate cancer	8.77e-06	0.000167	CcSEcCtD
Bicalutamide—Haemoglobin—Doxorubicin—prostate cancer	8.73e-06	0.000166	CcSEcCtD
Bicalutamide—Musculoskeletal discomfort—Capecitabine—prostate cancer	8.73e-06	0.000166	CcSEcCtD
Bicalutamide—Cardiac disorder—Epirubicin—prostate cancer	8.72e-06	0.000166	CcSEcCtD
Bicalutamide—Rhinitis—Doxorubicin—prostate cancer	8.71e-06	0.000165	CcSEcCtD
Bicalutamide—Dyspepsia—Docetaxel—prostate cancer	8.71e-06	0.000165	CcSEcCtD
Bicalutamide—Haemorrhage—Doxorubicin—prostate cancer	8.69e-06	0.000165	CcSEcCtD
Bicalutamide—Insomnia—Capecitabine—prostate cancer	8.66e-06	0.000164	CcSEcCtD
Bicalutamide—Pharyngitis—Doxorubicin—prostate cancer	8.62e-06	0.000164	CcSEcCtD
Bicalutamide—Paraesthesia—Capecitabine—prostate cancer	8.6e-06	0.000163	CcSEcCtD
Bicalutamide—Decreased appetite—Docetaxel—prostate cancer	8.6e-06	0.000163	CcSEcCtD
Bicalutamide—Urinary tract disorder—Doxorubicin—prostate cancer	8.58e-06	0.000163	CcSEcCtD
Bicalutamide—Oedema peripheral—Doxorubicin—prostate cancer	8.56e-06	0.000163	CcSEcCtD
Bicalutamide—Gastrointestinal disorder—Docetaxel—prostate cancer	8.54e-06	0.000162	CcSEcCtD
Bicalutamide—Asthenia—Etoposide—prostate cancer	8.54e-06	0.000162	CcSEcCtD
Bicalutamide—Dyspnoea—Capecitabine—prostate cancer	8.54e-06	0.000162	CcSEcCtD
Bicalutamide—Oedema—Prednisone—prostate cancer	8.53e-06	0.000162	CcSEcCtD
Bicalutamide—Fatigue—Docetaxel—prostate cancer	8.53e-06	0.000162	CcSEcCtD
Bicalutamide—Angiopathy—Epirubicin—prostate cancer	8.52e-06	0.000162	CcSEcCtD
Bicalutamide—Urethral disorder—Doxorubicin—prostate cancer	8.52e-06	0.000162	CcSEcCtD
Bicalutamide—Nausea—Mitoxantrone—prostate cancer	8.5e-06	0.000161	CcSEcCtD
Bicalutamide—Immune system disorder—Epirubicin—prostate cancer	8.48e-06	0.000161	CcSEcCtD
Bicalutamide—Infection—Prednisone—prostate cancer	8.47e-06	0.000161	CcSEcCtD
Bicalutamide—Mediastinal disorder—Epirubicin—prostate cancer	8.46e-06	0.000161	CcSEcCtD
Bicalutamide—Constipation—Docetaxel—prostate cancer	8.46e-06	0.000161	CcSEcCtD
Bicalutamide—Pain—Docetaxel—prostate cancer	8.46e-06	0.000161	CcSEcCtD
Bicalutamide—Dyspepsia—Capecitabine—prostate cancer	8.43e-06	0.00016	CcSEcCtD
Bicalutamide—Chills—Epirubicin—prostate cancer	8.43e-06	0.00016	CcSEcCtD
Bicalutamide—Pruritus—Etoposide—prostate cancer	8.42e-06	0.00016	CcSEcCtD
Bicalutamide—Shock—Prednisone—prostate cancer	8.39e-06	0.000159	CcSEcCtD
Bicalutamide—Arrhythmia—Epirubicin—prostate cancer	8.39e-06	0.000159	CcSEcCtD
Bicalutamide—Visual impairment—Doxorubicin—prostate cancer	8.37e-06	0.000159	CcSEcCtD
Bicalutamide—Nervous system disorder—Prednisone—prostate cancer	8.37e-06	0.000159	CcSEcCtD
Bicalutamide—Decreased appetite—Capecitabine—prostate cancer	8.33e-06	0.000158	CcSEcCtD
Bicalutamide—Alopecia—Epirubicin—prostate cancer	8.3e-06	0.000158	CcSEcCtD
Bicalutamide—Skin disorder—Prednisone—prostate cancer	8.29e-06	0.000157	CcSEcCtD
Bicalutamide—Gastrointestinal disorder—Capecitabine—prostate cancer	8.27e-06	0.000157	CcSEcCtD
Bicalutamide—Fatigue—Capecitabine—prostate cancer	8.26e-06	0.000157	CcSEcCtD
Bicalutamide—Hyperhidrosis—Prednisone—prostate cancer	8.25e-06	0.000157	CcSEcCtD
Bicalutamide—Mental disorder—Epirubicin—prostate cancer	8.23e-06	0.000156	CcSEcCtD
Bicalutamide—Constipation—Capecitabine—prostate cancer	8.19e-06	0.000156	CcSEcCtD
Bicalutamide—Pain—Capecitabine—prostate cancer	8.19e-06	0.000156	CcSEcCtD
Bicalutamide—Malnutrition—Epirubicin—prostate cancer	8.17e-06	0.000155	CcSEcCtD
Bicalutamide—Feeling abnormal—Docetaxel—prostate cancer	8.15e-06	0.000155	CcSEcCtD
Bicalutamide—Diarrhoea—Etoposide—prostate cancer	8.14e-06	0.000155	CcSEcCtD
Bicalutamide—Anorexia—Prednisone—prostate cancer	8.13e-06	0.000154	CcSEcCtD
Bicalutamide—Gastrointestinal pain—Docetaxel—prostate cancer	8.09e-06	0.000154	CcSEcCtD
Bicalutamide—Cardiac disorder—Doxorubicin—prostate cancer	8.06e-06	0.000153	CcSEcCtD
Bicalutamide—Flatulence—Epirubicin—prostate cancer	8.06e-06	0.000153	CcSEcCtD
Bicalutamide—Tension—Epirubicin—prostate cancer	8.02e-06	0.000152	CcSEcCtD
Bicalutamide—Nervousness—Epirubicin—prostate cancer	7.94e-06	0.000151	CcSEcCtD
Bicalutamide—Back pain—Epirubicin—prostate cancer	7.91e-06	0.00015	CcSEcCtD
Bicalutamide—Feeling abnormal—Capecitabine—prostate cancer	7.89e-06	0.00015	CcSEcCtD
Bicalutamide—Angiopathy—Doxorubicin—prostate cancer	7.88e-06	0.00015	CcSEcCtD
Bicalutamide—Dizziness—Etoposide—prostate cancer	7.87e-06	0.000149	CcSEcCtD
Bicalutamide—Muscle spasms—Epirubicin—prostate cancer	7.86e-06	0.000149	CcSEcCtD
Bicalutamide—Immune system disorder—Doxorubicin—prostate cancer	7.85e-06	0.000149	CcSEcCtD
Bicalutamide—Gastrointestinal pain—Capecitabine—prostate cancer	7.83e-06	0.000149	CcSEcCtD
Bicalutamide—Mediastinal disorder—Doxorubicin—prostate cancer	7.83e-06	0.000149	CcSEcCtD
Bicalutamide—Body temperature increased—Docetaxel—prostate cancer	7.82e-06	0.000148	CcSEcCtD
Bicalutamide—Abdominal pain—Docetaxel—prostate cancer	7.82e-06	0.000148	CcSEcCtD
Bicalutamide—Chills—Doxorubicin—prostate cancer	7.8e-06	0.000148	CcSEcCtD
Bicalutamide—Musculoskeletal discomfort—Prednisone—prostate cancer	7.77e-06	0.000148	CcSEcCtD
Bicalutamide—Arrhythmia—Doxorubicin—prostate cancer	7.76e-06	0.000147	CcSEcCtD
Bicalutamide—Insomnia—Prednisone—prostate cancer	7.72e-06	0.000147	CcSEcCtD
Bicalutamide—Alopecia—Doxorubicin—prostate cancer	7.68e-06	0.000146	CcSEcCtD
Bicalutamide—Paraesthesia—Prednisone—prostate cancer	7.66e-06	0.000145	CcSEcCtD
Bicalutamide—Mental disorder—Doxorubicin—prostate cancer	7.61e-06	0.000145	CcSEcCtD
Bicalutamide—Urticaria—Capecitabine—prostate cancer	7.61e-06	0.000144	CcSEcCtD
Bicalutamide—Abdominal pain—Capecitabine—prostate cancer	7.57e-06	0.000144	CcSEcCtD
Bicalutamide—Body temperature increased—Capecitabine—prostate cancer	7.57e-06	0.000144	CcSEcCtD
Bicalutamide—Vomiting—Etoposide—prostate cancer	7.57e-06	0.000144	CcSEcCtD
Bicalutamide—Malnutrition—Doxorubicin—prostate cancer	7.56e-06	0.000144	CcSEcCtD
Bicalutamide—Anaemia—Epirubicin—prostate cancer	7.56e-06	0.000143	CcSEcCtD
Bicalutamide—Dyspepsia—Prednisone—prostate cancer	7.51e-06	0.000143	CcSEcCtD
Bicalutamide—Rash—Etoposide—prostate cancer	7.5e-06	0.000143	CcSEcCtD
Bicalutamide—Dermatitis—Etoposide—prostate cancer	7.5e-06	0.000142	CcSEcCtD
Bicalutamide—Headache—Etoposide—prostate cancer	7.46e-06	0.000142	CcSEcCtD
Bicalutamide—Flatulence—Doxorubicin—prostate cancer	7.45e-06	0.000142	CcSEcCtD
Bicalutamide—Tension—Doxorubicin—prostate cancer	7.42e-06	0.000141	CcSEcCtD
Bicalutamide—Decreased appetite—Prednisone—prostate cancer	7.42e-06	0.000141	CcSEcCtD
Bicalutamide—Fatigue—Prednisone—prostate cancer	7.35e-06	0.00014	CcSEcCtD
Bicalutamide—Nervousness—Doxorubicin—prostate cancer	7.35e-06	0.00014	CcSEcCtD
Bicalutamide—Syncope—Epirubicin—prostate cancer	7.33e-06	0.000139	CcSEcCtD
Bicalutamide—Back pain—Doxorubicin—prostate cancer	7.32e-06	0.000139	CcSEcCtD
Bicalutamide—Constipation—Prednisone—prostate cancer	7.29e-06	0.000139	CcSEcCtD
Bicalutamide—Hypersensitivity—Docetaxel—prostate cancer	7.29e-06	0.000138	CcSEcCtD
Bicalutamide—Muscle spasms—Doxorubicin—prostate cancer	7.27e-06	0.000138	CcSEcCtD
Bicalutamide—Loss of consciousness—Epirubicin—prostate cancer	7.19e-06	0.000136	CcSEcCtD
Bicalutamide—Cough—Epirubicin—prostate cancer	7.13e-06	0.000135	CcSEcCtD
Bicalutamide—Asthenia—Docetaxel—prostate cancer	7.1e-06	0.000135	CcSEcCtD
Bicalutamide—Nausea—Etoposide—prostate cancer	7.07e-06	0.000134	CcSEcCtD
Bicalutamide—Hypertension—Epirubicin—prostate cancer	7.06e-06	0.000134	CcSEcCtD
Bicalutamide—Hypersensitivity—Capecitabine—prostate cancer	7.06e-06	0.000134	CcSEcCtD
Bicalutamide—Feeling abnormal—Prednisone—prostate cancer	7.03e-06	0.000133	CcSEcCtD
Bicalutamide—Pruritus—Docetaxel—prostate cancer	7e-06	0.000133	CcSEcCtD
Bicalutamide—Anaemia—Doxorubicin—prostate cancer	6.99e-06	0.000133	CcSEcCtD
Bicalutamide—Gastrointestinal pain—Prednisone—prostate cancer	6.98e-06	0.000132	CcSEcCtD
Bicalutamide—Chest pain—Epirubicin—prostate cancer	6.96e-06	0.000132	CcSEcCtD
Bicalutamide—Myalgia—Epirubicin—prostate cancer	6.96e-06	0.000132	CcSEcCtD
Bicalutamide—Anxiety—Epirubicin—prostate cancer	6.94e-06	0.000132	CcSEcCtD
Bicalutamide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	6.91e-06	0.000131	CcSEcCtD
Bicalutamide—Asthenia—Capecitabine—prostate cancer	6.87e-06	0.00013	CcSEcCtD
Bicalutamide—Dry mouth—Epirubicin—prostate cancer	6.81e-06	0.000129	CcSEcCtD
Bicalutamide—Syncope—Doxorubicin—prostate cancer	6.78e-06	0.000129	CcSEcCtD
Bicalutamide—Urticaria—Prednisone—prostate cancer	6.78e-06	0.000129	CcSEcCtD
Bicalutamide—Pruritus—Capecitabine—prostate cancer	6.78e-06	0.000129	CcSEcCtD
Bicalutamide—Diarrhoea—Docetaxel—prostate cancer	6.77e-06	0.000129	CcSEcCtD
Bicalutamide—Body temperature increased—Prednisone—prostate cancer	6.74e-06	0.000128	CcSEcCtD
Bicalutamide—Abdominal pain—Prednisone—prostate cancer	6.74e-06	0.000128	CcSEcCtD
Bicalutamide—Confusional state—Epirubicin—prostate cancer	6.73e-06	0.000128	CcSEcCtD
Bicalutamide—Oedema—Epirubicin—prostate cancer	6.67e-06	0.000127	CcSEcCtD
Bicalutamide—Loss of consciousness—Doxorubicin—prostate cancer	6.65e-06	0.000126	CcSEcCtD
Bicalutamide—Infection—Epirubicin—prostate cancer	6.63e-06	0.000126	CcSEcCtD
Bicalutamide—Cough—Doxorubicin—prostate cancer	6.6e-06	0.000125	CcSEcCtD
Bicalutamide—Shock—Epirubicin—prostate cancer	6.56e-06	0.000125	CcSEcCtD
Bicalutamide—Diarrhoea—Capecitabine—prostate cancer	6.55e-06	0.000124	CcSEcCtD
Bicalutamide—Nervous system disorder—Epirubicin—prostate cancer	6.54e-06	0.000124	CcSEcCtD
Bicalutamide—Dizziness—Docetaxel—prostate cancer	6.54e-06	0.000124	CcSEcCtD
Bicalutamide—Thrombocytopenia—Epirubicin—prostate cancer	6.53e-06	0.000124	CcSEcCtD
Bicalutamide—Hypertension—Doxorubicin—prostate cancer	6.53e-06	0.000124	CcSEcCtD
Bicalutamide—Skin disorder—Epirubicin—prostate cancer	6.48e-06	0.000123	CcSEcCtD
Bicalutamide—Hyperhidrosis—Epirubicin—prostate cancer	6.45e-06	0.000122	CcSEcCtD
Bicalutamide—Chest pain—Doxorubicin—prostate cancer	6.44e-06	0.000122	CcSEcCtD
Bicalutamide—Myalgia—Doxorubicin—prostate cancer	6.44e-06	0.000122	CcSEcCtD
Bicalutamide—Anxiety—Doxorubicin—prostate cancer	6.42e-06	0.000122	CcSEcCtD
Bicalutamide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	6.4e-06	0.000121	CcSEcCtD
Bicalutamide—Anorexia—Epirubicin—prostate cancer	6.36e-06	0.000121	CcSEcCtD
Bicalutamide—Dizziness—Capecitabine—prostate cancer	6.33e-06	0.00012	CcSEcCtD
Bicalutamide—Dry mouth—Doxorubicin—prostate cancer	6.3e-06	0.00012	CcSEcCtD
Bicalutamide—Vomiting—Docetaxel—prostate cancer	6.29e-06	0.000119	CcSEcCtD
Bicalutamide—Hypersensitivity—Prednisone—prostate cancer	6.29e-06	0.000119	CcSEcCtD
Bicalutamide—Rash—Docetaxel—prostate cancer	6.24e-06	0.000118	CcSEcCtD
Bicalutamide—Dermatitis—Docetaxel—prostate cancer	6.23e-06	0.000118	CcSEcCtD
Bicalutamide—Confusional state—Doxorubicin—prostate cancer	6.22e-06	0.000118	CcSEcCtD
Bicalutamide—Headache—Docetaxel—prostate cancer	6.2e-06	0.000118	CcSEcCtD
Bicalutamide—Oedema—Doxorubicin—prostate cancer	6.17e-06	0.000117	CcSEcCtD
Bicalutamide—Infection—Doxorubicin—prostate cancer	6.13e-06	0.000116	CcSEcCtD
Bicalutamide—Asthenia—Prednisone—prostate cancer	6.12e-06	0.000116	CcSEcCtD
Bicalutamide—Vomiting—Capecitabine—prostate cancer	6.09e-06	0.000116	CcSEcCtD
Bicalutamide—Musculoskeletal discomfort—Epirubicin—prostate cancer	6.08e-06	0.000115	CcSEcCtD
Bicalutamide—Shock—Doxorubicin—prostate cancer	6.07e-06	0.000115	CcSEcCtD
Bicalutamide—Nervous system disorder—Doxorubicin—prostate cancer	6.05e-06	0.000115	CcSEcCtD
Bicalutamide—Thrombocytopenia—Doxorubicin—prostate cancer	6.04e-06	0.000115	CcSEcCtD
Bicalutamide—Rash—Capecitabine—prostate cancer	6.04e-06	0.000115	CcSEcCtD
Bicalutamide—Pruritus—Prednisone—prostate cancer	6.04e-06	0.000115	CcSEcCtD
Bicalutamide—Insomnia—Epirubicin—prostate cancer	6.03e-06	0.000115	CcSEcCtD
Bicalutamide—Dermatitis—Capecitabine—prostate cancer	6.03e-06	0.000115	CcSEcCtD
Bicalutamide—Headache—Capecitabine—prostate cancer	6e-06	0.000114	CcSEcCtD
Bicalutamide—Skin disorder—Doxorubicin—prostate cancer	6e-06	0.000114	CcSEcCtD
Bicalutamide—Paraesthesia—Epirubicin—prostate cancer	5.99e-06	0.000114	CcSEcCtD
Bicalutamide—Hyperhidrosis—Doxorubicin—prostate cancer	5.97e-06	0.000113	CcSEcCtD
Bicalutamide—Dyspnoea—Epirubicin—prostate cancer	5.95e-06	0.000113	CcSEcCtD
Bicalutamide—Somnolence—Epirubicin—prostate cancer	5.93e-06	0.000113	CcSEcCtD
Bicalutamide—Anorexia—Doxorubicin—prostate cancer	5.88e-06	0.000112	CcSEcCtD
Bicalutamide—Nausea—Docetaxel—prostate cancer	5.88e-06	0.000112	CcSEcCtD
Bicalutamide—Dyspepsia—Epirubicin—prostate cancer	5.87e-06	0.000112	CcSEcCtD
Bicalutamide—Diarrhoea—Prednisone—prostate cancer	5.84e-06	0.000111	CcSEcCtD
Bicalutamide—Decreased appetite—Epirubicin—prostate cancer	5.8e-06	0.00011	CcSEcCtD
Bicalutamide—Gastrointestinal disorder—Epirubicin—prostate cancer	5.76e-06	0.000109	CcSEcCtD
Bicalutamide—Fatigue—Epirubicin—prostate cancer	5.75e-06	0.000109	CcSEcCtD
Bicalutamide—Constipation—Epirubicin—prostate cancer	5.71e-06	0.000108	CcSEcCtD
Bicalutamide—Pain—Epirubicin—prostate cancer	5.71e-06	0.000108	CcSEcCtD
Bicalutamide—Nausea—Capecitabine—prostate cancer	5.69e-06	0.000108	CcSEcCtD
Bicalutamide—Dizziness—Prednisone—prostate cancer	5.64e-06	0.000107	CcSEcCtD
Bicalutamide—Musculoskeletal discomfort—Doxorubicin—prostate cancer	5.62e-06	0.000107	CcSEcCtD
Bicalutamide—Insomnia—Doxorubicin—prostate cancer	5.58e-06	0.000106	CcSEcCtD
Bicalutamide—Paraesthesia—Doxorubicin—prostate cancer	5.54e-06	0.000105	CcSEcCtD
Bicalutamide—Dyspnoea—Doxorubicin—prostate cancer	5.5e-06	0.000105	CcSEcCtD
Bicalutamide—Feeling abnormal—Epirubicin—prostate cancer	5.5e-06	0.000104	CcSEcCtD
Bicalutamide—Somnolence—Doxorubicin—prostate cancer	5.49e-06	0.000104	CcSEcCtD
Bicalutamide—Gastrointestinal pain—Epirubicin—prostate cancer	5.46e-06	0.000104	CcSEcCtD
Bicalutamide—Dyspepsia—Doxorubicin—prostate cancer	5.43e-06	0.000103	CcSEcCtD
Bicalutamide—Vomiting—Prednisone—prostate cancer	5.42e-06	0.000103	CcSEcCtD
Bicalutamide—Rash—Prednisone—prostate cancer	5.38e-06	0.000102	CcSEcCtD
Bicalutamide—Dermatitis—Prednisone—prostate cancer	5.37e-06	0.000102	CcSEcCtD
Bicalutamide—Decreased appetite—Doxorubicin—prostate cancer	5.37e-06	0.000102	CcSEcCtD
Bicalutamide—Headache—Prednisone—prostate cancer	5.34e-06	0.000101	CcSEcCtD
Bicalutamide—Gastrointestinal disorder—Doxorubicin—prostate cancer	5.33e-06	0.000101	CcSEcCtD
Bicalutamide—Fatigue—Doxorubicin—prostate cancer	5.32e-06	0.000101	CcSEcCtD
Bicalutamide—Urticaria—Epirubicin—prostate cancer	5.3e-06	0.000101	CcSEcCtD
Bicalutamide—Pain—Doxorubicin—prostate cancer	5.28e-06	0.0001	CcSEcCtD
Bicalutamide—Constipation—Doxorubicin—prostate cancer	5.28e-06	0.0001	CcSEcCtD
Bicalutamide—Body temperature increased—Epirubicin—prostate cancer	5.27e-06	0.0001	CcSEcCtD
Bicalutamide—Abdominal pain—Epirubicin—prostate cancer	5.27e-06	0.0001	CcSEcCtD
Bicalutamide—Feeling abnormal—Doxorubicin—prostate cancer	5.09e-06	9.66e-05	CcSEcCtD
Bicalutamide—Nausea—Prednisone—prostate cancer	5.07e-06	9.62e-05	CcSEcCtD
Bicalutamide—Gastrointestinal pain—Doxorubicin—prostate cancer	5.05e-06	9.59e-05	CcSEcCtD
Bicalutamide—Hypersensitivity—Epirubicin—prostate cancer	4.92e-06	9.33e-05	CcSEcCtD
Bicalutamide—Urticaria—Doxorubicin—prostate cancer	4.9e-06	9.31e-05	CcSEcCtD
Bicalutamide—Body temperature increased—Doxorubicin—prostate cancer	4.88e-06	9.27e-05	CcSEcCtD
Bicalutamide—Abdominal pain—Doxorubicin—prostate cancer	4.88e-06	9.27e-05	CcSEcCtD
Bicalutamide—Asthenia—Epirubicin—prostate cancer	4.79e-06	9.09e-05	CcSEcCtD
Bicalutamide—Pruritus—Epirubicin—prostate cancer	4.72e-06	8.96e-05	CcSEcCtD
Bicalutamide—Diarrhoea—Epirubicin—prostate cancer	4.56e-06	8.67e-05	CcSEcCtD
Bicalutamide—Hypersensitivity—Doxorubicin—prostate cancer	4.55e-06	8.64e-05	CcSEcCtD
Bicalutamide—Asthenia—Doxorubicin—prostate cancer	4.43e-06	8.41e-05	CcSEcCtD
Bicalutamide—Dizziness—Epirubicin—prostate cancer	4.41e-06	8.38e-05	CcSEcCtD
Bicalutamide—Pruritus—Doxorubicin—prostate cancer	4.37e-06	8.29e-05	CcSEcCtD
Bicalutamide—Vomiting—Epirubicin—prostate cancer	4.24e-06	8.06e-05	CcSEcCtD
Bicalutamide—Diarrhoea—Doxorubicin—prostate cancer	4.22e-06	8.02e-05	CcSEcCtD
Bicalutamide—Rash—Epirubicin—prostate cancer	4.21e-06	7.99e-05	CcSEcCtD
Bicalutamide—Dermatitis—Epirubicin—prostate cancer	4.2e-06	7.98e-05	CcSEcCtD
Bicalutamide—Headache—Epirubicin—prostate cancer	4.18e-06	7.94e-05	CcSEcCtD
Bicalutamide—Dizziness—Doxorubicin—prostate cancer	4.08e-06	7.75e-05	CcSEcCtD
Bicalutamide—Nausea—Epirubicin—prostate cancer	3.96e-06	7.53e-05	CcSEcCtD
Bicalutamide—Vomiting—Doxorubicin—prostate cancer	3.93e-06	7.45e-05	CcSEcCtD
Bicalutamide—Rash—Doxorubicin—prostate cancer	3.89e-06	7.39e-05	CcSEcCtD
Bicalutamide—Dermatitis—Doxorubicin—prostate cancer	3.89e-06	7.38e-05	CcSEcCtD
Bicalutamide—Headache—Doxorubicin—prostate cancer	3.87e-06	7.34e-05	CcSEcCtD
Bicalutamide—Nausea—Doxorubicin—prostate cancer	3.67e-06	6.96e-05	CcSEcCtD
Bicalutamide—CYP2D6—Metabolism—GSTA1—prostate cancer	1.84e-06	7.38e-05	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—GSTA1—prostate cancer	1.83e-06	7.31e-05	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—NAT2—prostate cancer	1.82e-06	7.29e-05	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—HSD3B2—prostate cancer	1.82e-06	7.29e-05	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—GSTO1—prostate cancer	1.82e-06	7.29e-05	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—SLC22A1—prostate cancer	1.81e-06	7.25e-05	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—GSTO1—prostate cancer	1.81e-06	7.23e-05	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—HSD3B2—prostate cancer	1.81e-06	7.23e-05	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—NAT2—prostate cancer	1.81e-06	7.23e-05	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—CAV1—prostate cancer	1.79e-06	7.17e-05	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—SULT2A1—prostate cancer	1.77e-06	7.07e-05	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—PLCB2—prostate cancer	1.75e-06	6.99e-05	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—LRP2—prostate cancer	1.75e-06	6.99e-05	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—CYP2C18—prostate cancer	1.75e-06	6.99e-05	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—TNFRSF21—prostate cancer	1.74e-06	6.96e-05	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—MED12—prostate cancer	1.74e-06	6.95e-05	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—PPARA—prostate cancer	1.74e-06	6.95e-05	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—PLCB2—prostate cancer	1.73e-06	6.93e-05	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—LRP2—prostate cancer	1.73e-06	6.93e-05	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—CYP2C18—prostate cancer	1.73e-06	6.93e-05	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—GNG5—prostate cancer	1.72e-06	6.9e-05	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—P4HB—prostate cancer	1.71e-06	6.86e-05	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—P4HB—prostate cancer	1.7e-06	6.8e-05	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—MTAP—prostate cancer	1.69e-06	6.77e-05	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—CYP7B1—prostate cancer	1.69e-06	6.77e-05	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—SLC22A1—prostate cancer	1.67e-06	6.67e-05	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—NCOA3—prostate cancer	1.66e-06	6.65e-05	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—SLC22A1—prostate cancer	1.65e-06	6.61e-05	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—SULT1E1—prostate cancer	1.65e-06	6.6e-05	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—SRD5A1—prostate cancer	1.65e-06	6.6e-05	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—CAV1—prostate cancer	1.63e-06	6.54e-05	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CG—prostate cancer	1.63e-06	6.53e-05	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—SULT2A1—prostate cancer	1.62e-06	6.5e-05	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—SULT2A1—prostate cancer	1.61e-06	6.44e-05	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—MED12—prostate cancer	1.6e-06	6.4e-05	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—GNG5—prostate cancer	1.59e-06	6.35e-05	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—MED12—prostate cancer	1.58e-06	6.34e-05	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—HPGDS—prostate cancer	1.58e-06	6.34e-05	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—ACSL4—prostate cancer	1.57e-06	6.29e-05	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—HSD17B3—prostate cancer	1.57e-06	6.29e-05	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—GNG5—prostate cancer	1.57e-06	6.29e-05	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—GSTT1—prostate cancer	1.54e-06	6.15e-05	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—ACHE—prostate cancer	1.54e-06	6.15e-05	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—NCOA3—prostate cancer	1.53e-06	6.11e-05	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—CYP2A6—prostate cancer	1.52e-06	6.08e-05	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—NCOA3—prostate cancer	1.51e-06	6.06e-05	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—prostate cancer	1.51e-06	6.05e-05	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—UMPS—prostate cancer	1.51e-06	6.03e-05	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—PHGDH—prostate cancer	1.51e-06	6.03e-05	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—ARG2—prostate cancer	1.51e-06	6.03e-05	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—prostate cancer	1.49e-06	5.95e-05	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—LDHB—prostate cancer	1.48e-06	5.92e-05	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—AKR1C3—prostate cancer	1.48e-06	5.91e-05	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—PRKACB—prostate cancer	1.47e-06	5.88e-05	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—HPGDS—prostate cancer	1.46e-06	5.83e-05	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—CYP17A1—prostate cancer	1.45e-06	5.82e-05	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—CYP3A5—prostate cancer	1.45e-06	5.81e-05	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—CYP2C19—prostate cancer	1.45e-06	5.79e-05	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—HPGDS—prostate cancer	1.44e-06	5.78e-05	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—CYP2C19—prostate cancer	1.44e-06	5.74e-05	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CD—prostate cancer	1.43e-06	5.74e-05	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—GSTT1—prostate cancer	1.41e-06	5.66e-05	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—ACHE—prostate cancer	1.41e-06	5.66e-05	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—PDHA1—prostate cancer	1.4e-06	5.61e-05	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—GSTA3—prostate cancer	1.4e-06	5.61e-05	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—TCN2—prostate cancer	1.4e-06	5.61e-05	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—UCP3—prostate cancer	1.4e-06	5.61e-05	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—ACHE—prostate cancer	1.4e-06	5.61e-05	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—GSTT1—prostate cancer	1.4e-06	5.61e-05	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—CYP2A6—prostate cancer	1.4e-06	5.59e-05	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—NCOA2—prostate cancer	1.39e-06	5.55e-05	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—CYP2A6—prostate cancer	1.38e-06	5.54e-05	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—prostate cancer	1.38e-06	5.52e-05	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—AKR1C3—prostate cancer	1.36e-06	5.44e-05	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—PRKACB—prostate cancer	1.35e-06	5.41e-05	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—AKR1C3—prostate cancer	1.35e-06	5.39e-05	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—PRKACB—prostate cancer	1.34e-06	5.36e-05	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—CYP17A1—prostate cancer	1.34e-06	5.35e-05	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—SLC22A3—prostate cancer	1.34e-06	5.35e-05	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—HSD3B1—prostate cancer	1.34e-06	5.35e-05	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—CYP17A1—prostate cancer	1.33e-06	5.31e-05	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—SLC5A5—prostate cancer	1.32e-06	5.29e-05	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—prostate cancer	1.31e-06	5.23e-05	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—CYP2E1—prostate cancer	1.29e-06	5.17e-05	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—GSTA4—prostate cancer	1.28e-06	5.13e-05	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—TBXAS1—prostate cancer	1.28e-06	5.13e-05	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—NQO1—prostate cancer	1.28e-06	5.11e-05	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—NCOA2—prostate cancer	1.27e-06	5.1e-05	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—NCOA2—prostate cancer	1.26e-06	5.06e-05	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—TH—prostate cancer	1.26e-06	5.04e-05	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	1.25e-06	5e-05	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—GSTA2—prostate cancer	1.25e-06	5e-05	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—CYP3A4—prostate cancer	1.25e-06	4.98e-05	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	1.24e-06	4.96e-05	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—SULT1A1—prostate cancer	1.23e-06	4.94e-05	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—ABCG5—prostate cancer	1.23e-06	4.94e-05	CbGpPWpGaD
Bicalutamide—AR—Gene Expression—MYC—prostate cancer	1.23e-06	4.93e-05	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—CYP1B1—prostate cancer	1.22e-06	4.9e-05	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—SLC5A5—prostate cancer	1.22e-06	4.87e-05	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—SLC5A5—prostate cancer	1.21e-06	4.82e-05	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—GSTA1—prostate cancer	1.21e-06	4.82e-05	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—HSD3B2—prostate cancer	1.19e-06	4.77e-05	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—NAT2—prostate cancer	1.19e-06	4.77e-05	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—GSTO1—prostate cancer	1.19e-06	4.77e-05	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—CYP2E1—prostate cancer	1.19e-06	4.75e-05	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—GGT1—prostate cancer	1.19e-06	4.74e-05	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—CYP2E1—prostate cancer	1.18e-06	4.71e-05	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—NQO1—prostate cancer	1.17e-06	4.7e-05	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—NCOA1—prostate cancer	1.17e-06	4.67e-05	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—NQO1—prostate cancer	1.16e-06	4.66e-05	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—TH—prostate cancer	1.16e-06	4.63e-05	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—CYP19A1—prostate cancer	1.15e-06	4.61e-05	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—TH—prostate cancer	1.15e-06	4.59e-05	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—CYP3A4—prostate cancer	1.15e-06	4.58e-05	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—PLCB2—prostate cancer	1.14e-06	4.57e-05	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—CYP2C18—prostate cancer	1.14e-06	4.57e-05	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—LRP2—prostate cancer	1.14e-06	4.57e-05	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	1.14e-06	4.56e-05	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—CYP3A4—prostate cancer	1.14e-06	4.54e-05	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	1.13e-06	4.52e-05	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—CYP1B1—prostate cancer	1.13e-06	4.51e-05	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—P4HB—prostate cancer	1.12e-06	4.48e-05	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—CYP1B1—prostate cancer	1.12e-06	4.47e-05	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—RXRA—prostate cancer	1.11e-06	4.45e-05	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—GGT1—prostate cancer	1.09e-06	4.36e-05	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—SLC22A1—prostate cancer	1.09e-06	4.36e-05	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—GGT1—prostate cancer	1.08e-06	4.33e-05	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	1.08e-06	4.32e-05	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—NCOA1—prostate cancer	1.07e-06	4.3e-05	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—COMT—prostate cancer	1.07e-06	4.28e-05	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—GSTP1—prostate cancer	1.07e-06	4.26e-05	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—NCOA1—prostate cancer	1.06e-06	4.26e-05	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—SULT2A1—prostate cancer	1.06e-06	4.25e-05	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—CYP19A1—prostate cancer	1.06e-06	4.24e-05	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—CYP19A1—prostate cancer	1.05e-06	4.2e-05	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—ITPR1—prostate cancer	1.05e-06	4.19e-05	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—MED12—prostate cancer	1.04e-06	4.18e-05	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—GNG5—prostate cancer	1.04e-06	4.15e-05	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—EP300—prostate cancer	1.03e-06	4.12e-05	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—RXRA—prostate cancer	1.02e-06	4.09e-05	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—RXRA—prostate cancer	1.01e-06	4.05e-05	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—NCOA3—prostate cancer	9.99e-07	4e-05	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—TYMS—prostate cancer	9.9e-07	3.96e-05	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	9.85e-07	3.94e-05	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—COMT—prostate cancer	9.84e-07	3.94e-05	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—GSTP1—prostate cancer	9.8e-07	3.92e-05	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—GSTM1—prostate cancer	9.79e-07	3.92e-05	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—COMT—prostate cancer	9.76e-07	3.9e-05	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—GSTP1—prostate cancer	9.71e-07	3.89e-05	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—ITPR1—prostate cancer	9.64e-07	3.86e-05	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—LPL—prostate cancer	9.61e-07	3.84e-05	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—ITPR1—prostate cancer	9.56e-07	3.82e-05	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—HPGDS—prostate cancer	9.53e-07	3.81e-05	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—CYP2C19—prostate cancer	9.47e-07	3.79e-05	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—EP300—prostate cancer	9.4e-07	3.76e-05	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—CYP1A1—prostate cancer	9.28e-07	3.71e-05	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—GSTT1—prostate cancer	9.24e-07	3.7e-05	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—ACHE—prostate cancer	9.24e-07	3.7e-05	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—ERCC2—prostate cancer	9.2e-07	3.68e-05	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—CYP2A6—prostate cancer	9.13e-07	3.65e-05	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—TYMS—prostate cancer	9.11e-07	3.64e-05	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—TYMS—prostate cancer	9.03e-07	3.61e-05	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—GSTM1—prostate cancer	9e-07	3.6e-05	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—GSTM1—prostate cancer	8.92e-07	3.57e-05	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—AKR1C3—prostate cancer	8.89e-07	3.56e-05	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—PRKACB—prostate cancer	8.84e-07	3.54e-05	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—LPL—prostate cancer	8.84e-07	3.54e-05	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—LPL—prostate cancer	8.76e-07	3.51e-05	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—CYP17A1—prostate cancer	8.75e-07	3.5e-05	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—MTHFR—prostate cancer	8.65e-07	3.46e-05	CbGpPWpGaD
Bicalutamide—AR—Gene Expression—AKT1—prostate cancer	8.54e-07	3.42e-05	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—CYP1A1—prostate cancer	8.53e-07	3.41e-05	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—PPARA—prostate cancer	8.49e-07	3.4e-05	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—ERCC2—prostate cancer	8.46e-07	3.39e-05	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—CYP1A1—prostate cancer	8.46e-07	3.39e-05	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—ERCC2—prostate cancer	8.39e-07	3.36e-05	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—NCOA2—prostate cancer	8.33e-07	3.34e-05	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—CAV1—prostate cancer	7.98e-07	3.19e-05	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—MTHFR—prostate cancer	7.96e-07	3.18e-05	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—SLC5A5—prostate cancer	7.95e-07	3.18e-05	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—MTHFR—prostate cancer	7.89e-07	3.16e-05	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—PPARA—prostate cancer	7.81e-07	3.12e-05	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—CYP2E1—prostate cancer	7.77e-07	3.11e-05	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—PPARA—prostate cancer	7.74e-07	3.1e-05	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—NQO1—prostate cancer	7.68e-07	3.07e-05	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	7.62e-07	3.05e-05	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—TH—prostate cancer	7.57e-07	3.03e-05	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—CYP1B1—prostate cancer	7.36e-07	2.95e-05	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—CAV1—prostate cancer	7.34e-07	2.94e-05	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—CAV1—prostate cancer	7.28e-07	2.91e-05	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—PIK3CG—prostate cancer	7.27e-07	2.91e-05	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—GGT1—prostate cancer	7.13e-07	2.85e-05	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—NCOA1—prostate cancer	7.02e-07	2.81e-05	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	6.95e-07	2.78e-05	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—CYP19A1—prostate cancer	6.92e-07	2.77e-05	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—INS—prostate cancer	6.88e-07	2.75e-05	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—CREBBP—prostate cancer	6.74e-07	2.7e-05	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—PIK3CG—prostate cancer	6.68e-07	2.67e-05	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—RXRA—prostate cancer	6.68e-07	2.67e-05	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—PIK3CG—prostate cancer	6.63e-07	2.65e-05	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—COMT—prostate cancer	6.44e-07	2.58e-05	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—GSTP1—prostate cancer	6.4e-07	2.56e-05	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—PIK3CD—prostate cancer	6.39e-07	2.56e-05	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—INS—prostate cancer	6.33e-07	2.53e-05	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—ITPR1—prostate cancer	6.3e-07	2.52e-05	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—INS—prostate cancer	6.27e-07	2.51e-05	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—CREBBP—prostate cancer	6.2e-07	2.48e-05	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—CREBBP—prostate cancer	6.14e-07	2.46e-05	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—NOS3—prostate cancer	6.03e-07	2.41e-05	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—TYMS—prostate cancer	5.95e-07	2.38e-05	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—GSTM1—prostate cancer	5.89e-07	2.36e-05	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—PIK3CD—prostate cancer	5.88e-07	2.35e-05	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—PIK3CD—prostate cancer	5.83e-07	2.33e-05	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—LPL—prostate cancer	5.78e-07	2.31e-05	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—CYP1A1—prostate cancer	5.58e-07	2.23e-05	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—PIK3CB—prostate cancer	5.57e-07	2.23e-05	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—NOS3—prostate cancer	5.55e-07	2.22e-05	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—ERCC2—prostate cancer	5.53e-07	2.21e-05	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—PTGS2—prostate cancer	5.52e-07	2.21e-05	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—NOS3—prostate cancer	5.5e-07	2.2e-05	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—MTHFR—prostate cancer	5.2e-07	2.08e-05	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—PIK3CB—prostate cancer	5.12e-07	2.05e-05	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—PPARA—prostate cancer	5.1e-07	2.04e-05	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—PIK3CB—prostate cancer	5.08e-07	2.03e-05	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—PTGS2—prostate cancer	5.08e-07	2.03e-05	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—PTGS2—prostate cancer	5.03e-07	2.01e-05	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—PTEN—prostate cancer	4.81e-07	1.93e-05	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—CAV1—prostate cancer	4.8e-07	1.92e-05	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—EP300—prostate cancer	4.59e-07	1.84e-05	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—PTEN—prostate cancer	4.43e-07	1.77e-05	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—PTEN—prostate cancer	4.39e-07	1.76e-05	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—PIK3CG—prostate cancer	4.37e-07	1.75e-05	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—EP300—prostate cancer	4.22e-07	1.69e-05	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—EP300—prostate cancer	4.18e-07	1.67e-05	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—INS—prostate cancer	4.14e-07	1.66e-05	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—CREBBP—prostate cancer	4.05e-07	1.62e-05	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—PIK3CD—prostate cancer	3.84e-07	1.54e-05	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—NOS3—prostate cancer	3.63e-07	1.45e-05	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—PIK3CA—prostate cancer	3.39e-07	1.36e-05	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—PIK3CB—prostate cancer	3.35e-07	1.34e-05	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—PTGS2—prostate cancer	3.32e-07	1.33e-05	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—PIK3CA—prostate cancer	3.12e-07	1.25e-05	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—PIK3CA—prostate cancer	3.1e-07	1.24e-05	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—PTEN—prostate cancer	2.89e-07	1.16e-05	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—AKT1—prostate cancer	2.77e-07	1.11e-05	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—EP300—prostate cancer	2.76e-07	1.1e-05	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—AKT1—prostate cancer	2.55e-07	1.02e-05	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—AKT1—prostate cancer	2.53e-07	1.01e-05	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—PIK3CA—prostate cancer	2.04e-07	8.17e-06	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—AKT1—prostate cancer	1.67e-07	6.67e-06	CbGpPWpGaD
